Metformin targets multiple signaling pathways in cancer.
Metformin targets multiple signaling pathways in cancer.
Chin J Cancer. 2017 Jan 26;36(1):17
Authors: Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian CN, Zhang J, Lu Y
Abstract
Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized.
PMID: 28126011 [PubMed - in process]
Source: Chinese Journal of Cancer - Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Insulin | Metformin | Oral Cancer | Stem Cell Therapy | Stem Cells